Published On: Wed, Oct 19th, 2016

Current Price Targets For Immune Pharmaceuticals Inc (IMNP)


Recently stock market analysts have updated their consensus ratings on shares of Immune Pharmaceuticals Inc (IMNP).

Most recent broker ratings

06/03/2016 – Immune Pharmaceuticals Inc had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 3 price target on the stock.

10/13/2015 – Immune Pharmaceuticals Inc had its “buy” rating reiterated by analysts at Chardan Capital. They now have a USD 6.5 price target on the stock.

10/08/2015 – Roth Capital began new coverage on Immune Pharmaceuticals Inc giving the company a “buy” rating. They now have a USD 6 price target on the stock.

06/11/2015 – MLV & Co began new coverage on Immune Pharmaceuticals Inc giving the company a “buy” rating. They now have a USD 6 price target on the stock.

Immune Pharmaceuticals Inc has a 50 day moving average of 0.30 and a 200 day moving average of 0.37. The stock’s market capitalization is 18.99M, it has a 52-week low of 0.20 and a 52-week high of 1.54.

The share price of the company (IMNP) was down -1.24% during the last trading session, with a high of 0.25 and the volume of Immune Pharmaceuticals Inc shares traded was 1516268.

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.